113 related articles for article (PubMed ID: 20202838)
41. Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
Skoumbourdis AP; Leclair CA; Stefan E; Turjanski AG; Maguire W; Titus SA; Huang R; Auld DS; Inglese J; Austin CP; Michnick SW; Xia M; Thomas CJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3686-92. PubMed ID: 19464886
[TBL] [Abstract][Full Text] [Related]
42. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
43. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
[TBL] [Abstract][Full Text] [Related]
44. Tetrahydroindolizinone NK1 antagonists.
Bao J; Lu H; Morriello GJ; Carlson EJ; Wheeldon A; Chicchi GG; Kurtz MM; Tsao KL; Zheng S; Tong X; Mills SG; DeVita RJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2354-8. PubMed ID: 20188553
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
46. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
[TBL] [Abstract][Full Text] [Related]
47. New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
Bruno O; Romussi A; Spallarossa A; Brullo C; Schenone S; Bondavalli F; Vanthuyne N; Roussel C
J Med Chem; 2009 Nov; 52(21):6546-57. PubMed ID: 19827751
[TBL] [Abstract][Full Text] [Related]
48. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
[No Abstract] [Full Text] [Related]
49. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
[TBL] [Abstract][Full Text] [Related]
51. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
52. Phosphodiesterase 4 conformers: preparation of recombinant enzymes and assay for inhibitors.
Bardelle C; Smales C; Ito M; Nomoto K; Wong EY; Kato H; Saeki T; Staddon JM
Anal Biochem; 1999 Nov; 275(2):148-55. PubMed ID: 10552898
[TBL] [Abstract][Full Text] [Related]
53. Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere.
Raboisson P; Schultz D; Muller C; Reimund JM; Pinna G; Mathieu R; Bernard P; Do QT; Desjarlais RL; Justiano H; Lugnier C; Bourguignon JJ
Eur J Med Chem; 2008 Apr; 43(4):816-29. PubMed ID: 17640774
[TBL] [Abstract][Full Text] [Related]
54. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M
Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510
[TBL] [Abstract][Full Text] [Related]
55. Addressing species specific metabolism and solubility issues in a quinoline series of oral PDE4 inhibitors.
Lunniss C; Eldred C; Aston N; Craven A; Gohil K; Judkins B; Keeling S; Ranshaw L; Robinson E; Shipley T; Trivedi N
Bioorg Med Chem Lett; 2010 Jan; 20(1):137-40. PubMed ID: 19932963
[TBL] [Abstract][Full Text] [Related]
56. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
[TBL] [Abstract][Full Text] [Related]
58. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
59. Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Liao Y; Guo Y; Li S; Wang L; Tang Y; Li T; Chen W; Zhong G; Song G
Bioorg Med Chem Lett; 2018 Apr; 28(7):1188-1193. PubMed ID: 29545101
[TBL] [Abstract][Full Text] [Related]
60. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.
Guariento S; Bruno O; Fossa P; Cichero E
Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
